Portal de Periódicos da CAPES

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

2021; Lippincott Williams & Wilkins; Volume: 31; Issue: 6 Linguagem: Inglês

10.1097/fpc.0000000000000431

1744-6880

Juan Eduardo Megías‐Vericat, David Martínez‐Cuadrón, Marí­a José Herrero, Rebeca Rodríguez‐Veiga, Antonio Solana‐Altabella, Blanca Boluda, Octavio Ballesta‐López, Isabel Cano, Evelyn Acuña‐Cruz, José Cervera, José Luís Poveda, Miguel Á. Sanz, Salvador F. Aliño, Pau Montesinos,

DNA Repair Mechanisms

Objectives Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Methods Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway ( CBR3: rs1056892, rs8133052, NQO1: rs1800566, NQO2: rs1143684, NOS3: rs1799983, rs2070744) were evaluated in 225 adult de novo AML patients. Results The variant CBR3 rs8133052 was associated with lower hepatotoxicity ( P = 0.028). Wild-type genotype of NQO2 rs1143684 was related to higher complete remission ( P = 0.014), and the variant allele with greater gastrointestinal toxicity ( P = 0.024). However, the variant genotype of NQO1 rs1800566 was associated with mucositis ( P = 0.018), but heterozygous genotype showed less gastrointestinal toxicity ( P = 0.028) and thrombocytopenia ( P = 0.009). Protective effects against nephrotoxicity and thrombocytopenia were reported with variant NOS3 rs1799983 ( P = 0.006, P = 0.014), whereas carriers of NOS3 rs2070744 showed higher hepatotoxicity and thrombocytopenia ( P = 0.017, P = 0.013). Conclusions This study supports the influence of genetic variability of idarubicin metabolizing could be critical in predicting anthracycline-induced toxicities.